Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.
M BradburyM F SavardC StoberL ClemonsM ClemonsJ HiltonG PondL VandermeerSharon F McGeePublished in: Breast cancer research and treatment (2024)
Trials to investigate who can safely and effectively be treated with shorter durations of anti-HER2 therapy are needed. This study provides important insights to patients' perspectives on shorter durations of anti-HER2 treatment, and their concerns regarding potential increased cancer risk with less treatment.
Keyphrases
- early stage
- positive breast cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- radiation therapy
- squamous cell carcinoma
- prognostic factors
- combination therapy
- mesenchymal stem cells
- cell therapy
- patient reported outcomes
- smoking cessation
- patient reported
- locally advanced